

AMERICAN VIETNAMESE
BIOTECH INC

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

No. 35/2025/CV - AMV

*Explanation of the exception of the audit of
the consolidated financial statements for the
middle year of 2024*

Ho Chi Minh City, May 23, 2025

To: **- THE STATE SECURITIES COMMISSION;**
 - HANOI STOCK EXCHANGE.

Company Name : AMERICAN VIETNAMESE BIOTECH INC
Stock Code : AMV
Head Office : 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu
Address Ward, District 7, Ho Chi Minh City, Vietnam
Telephone : 024.321.51114 Website: <http://amvibiotech.com>
Persons who : Dang Nhi Nuong Position: Director
make
information
disclosures

Type of disclosure: ☐ 24 hours ☐ abnormal ☐ On Request ☒ periodically

Content of information disclosure (*):

Implementing the disclosure of information in accordance with Circular No. 96/2020/TT-BTC dated 16/11/2020 of the Ministry of Finance, American Vietnamese Biotech Inc would like to report to the Board of Directors and the Department on the explanation of audit opinions except in the Consolidated Financial Statements for the mid-year year 2024 audited by the Company Limited Audit of Nhan Tam Viet as follows:

1. On the mid-year consolidated financial statements for the year 2024 audited by Nhan Tam Viet Auditing Co., Ltd., there are the following exceptions:

*** Basis of conclusion except**

"Some associated companies have been established but have not yet formed or insignificant assets for production and business activities. The amount of capital contribution to these companies is 30,950,000,000 VND (explanation No. V.13). By the applicable audit procedures, we do not have sufficient basis to assess the reasonableness of the above investments as well as their impact on the consolidated financial statements for the first 6 months of the fiscal year ended 31 December 2024."

Explanation of the cause: Up to now, a number of affiliated companies are in the process of completing relevant procedures, and at the same time implementing the procurement of machinery and equipment for business activities in accordance with the set plan. With continuous efforts, the Company is focusing on accelerating the implementation of necessary steps to bring these associated companies into operation soon.



*** Basis of conclusion except**

"The parent company and its subsidiaries have paid in advance for goods and services to the seller but have not received the goods and services according to the terms of the contract. Up to the time of issuance of this financial statement, the Company has not received the goods or recovered the prepaid money with a value of VND 419,809,600,000 (as of January 1, 2024, it is VND 399,840,000,000). We have undertaken additional audit procedures but have not been able to gather sufficient appropriate evidence to assess the recoverability of these prepayments at the aforementioned times. Therefore, we are unable to give opinions on the recoverability of this advance payment as of 30/06/2024 as well as the impact of this issue on the Company's attached Mid-Year Consolidated Financial Statements."

Explanation of causes: Advance payments to the seller arising from contracts for the purchase of machinery, equipment, goods and services between the parent company, subsidiaries and suppliers. However, due to the influence of a number of objective factors such as delays in delivery progress from suppliers, market fluctuations, as well as adjustments to the handover plan, so far some goods and services corresponding to prepaid payments have not been handed over or withdrawn.

The company is continuing to work closely with suppliers to ensure delivery progress and timely recovery of the above-mentioned advance payments

*** Basis of conclusion except**

"On June 30, 2024, Viet My Hospital Investment Joint Stock Company is cooperating to invest in the medical waste centralized treatment area project with Sara Vung Tau Joint Stock Company in the amount of VND 61,717,000,000. By the time of the issuance of this report, the above project has not completed the procedures to come into operation. By audit procedures, we did not assess the effectiveness and recoverability of the above investment, as well as their impact on the consolidated financial statements for the first 6 months of the fiscal year ending December 31, 2024."

Explanation of the cause: Due to the long time to approve legal documents related to the project, including construction permits, environmental impact assessment and trial operation, the project has not been able to complete the necessary procedures to go into official operation. The company is currently actively coordinating with partners and working with competent agencies to speed up the progress and put the project into operation soon.

*** Basis of conclusion except**

"The company has invested in and installed machinery, equipment, software systems for storing and transmitting RIS-PACS medical images under lease contracts, cooperation with hospitals and medical centers with an investment cost of 67,541,800,532 VND as of June 30, 2024 (of which the value handed over to the hospital for use is 40,953,427,745 VND, not yet handed over to the hospital is 26,588,372,787 VND). In some hospitals, there has been revenue but due to the lack of specific and uniform guidance on payment for diagnostic imaging services based on the PACS system, due to the fact that the Company

023:
ÔNG
CỔ PH
UẤT K
VÀ TRAI
Y T
VIỆT
> - T.P

still does not have enough reliable basis to fully determine the economic benefits obtained from the lease. the above-mentioned cooperation. However, the Company has recorded depreciation expense for the assets handed over in the business results of the years, the accumulated depreciation value as of June 30, 2024 is VND 18,573,725,968 (of which VND 16,526,054,590 accumulated until December 31, 2023, depreciation in the first 6 months of 2024 is 2,047,671,378 VND). By the applicable audit procedures, we have not determined their impact on the financial statements for the first six months of the fiscal year ended December 31, 2024."

Explanation of the cause: Currently, the Ministry of Health has not yet issued specific regulatory documents and guidelines related to payment for diagnostic imaging services using the PACS system (not printing film). Therefore, the Company does not have sufficient legal basis and reliable data to clearly identify the economic benefits from related investment, association, leasing or cooperation activities.

Immediately after receiving official instructions from the competent authority, the Company will actively coordinate with partners to complete and agree on an appropriate implementation mechanism, ensure compliance with regulations and have a full basis for determining the economic efficiency of this business investment activity.

*** Basis of conclusion except**

"As of June 30, 2024, the value of unfinished capital construction costs for the procurement of machinery and equipment operating at clinics with an amount of VND 65,777,789,540 incurred for a long time has not been accepted, handed over and put into use. By audit procedures, we have not been able to estimate the fair value of this basic construction cost nor its impact on the 2024 Interim Consolidated Financial Statements."

Explanation of the cause: Due to the influence of a number of objective factors, the completion of investment in some clinics has been delayed and cannot be put into operation as planned. Currently, the Company is actively reviewing and accelerating the completion progress to soon put these clinics into official deployment and operation

- 2. The Consolidated Financial Statements for the mid-year of 2024 and the above information have been published by the Company on the Company's website at the following link:**

<https://amvibiotech.com/>

American Vietnamese Biotech Inc commits that the information provided above is honest and accurate.

Thank you very much!

996
TỶ
AN
DOANH
THIỆT
MỸ
HỒ CHÍ

Recipient:

- Ditto.
- Save VP.

AMERICAN VIETNAMESE



BIOTECH INC

GIÁM ĐỐC

Dặng Nhị Nương

